Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry
Cenobamate (CNB) is a new anti-seizure medication (ASM) recently introduced in clinical practice after approval by the FDA and EMA for the add-on treatment of focal onset seizures in adult patients. Although its mechanism of action has not been fully understood, CNB showed promising clinical efficac...
Main Authors: | Linda Molteni, Bruno Charlier, Albino Coglianese, Viviana Izzo, Giovanni Assenza, Pierantonio Menna, Ugo de Grazia, Annachiara D’Urso |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/29/4/884 |
Similar Items
-
Development and Validation of a UHPLC–MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples
by: Bruno Charlier, et al.
Published: (2022-10-01) -
Safety and efficacy of cenobamate in patients with uncontrolled focal seizures - a review of the literature
by: Zofia Pietrzak, et al.
Published: (2022-02-01) -
Critical Appraisal of Cenobamate as Adjunctive Treatment of Focal Seizures in Adults
by: Zaccara G, et al.
Published: (2021-11-01) -
Development of a stability indicating high-performance liquid chromatography method for determination of cenobamate: study of basic degradation kinetics
by: Samah F. EL-Malla, et al.
Published: (2024-04-01) -
Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature
by: Jamir Pitton Rissardo, et al.
Published: (2023-07-01)